PFS is often used as a surrogate endpoint for regulatory approvals of new cancer treatments. Regulatory agencies like the FDA and EMA may grant accelerated approvals based on PFS data, especially when the treatment shows a significant improvement in delaying disease progression. This allows patients earlier access to potentially beneficial treatments while further data on overall survival is being collected.
